H
Hidetaka Uramoto
Researcher at Kanazawa Medical University
Publications - 375
Citations - 7665
Hidetaka Uramoto is an academic researcher from Kanazawa Medical University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 38, co-authored 351 publications receiving 6740 citations. Previous affiliations of Hidetaka Uramoto include University of Occupational and Environmental Health Japan.
Papers
More filters
Journal ArticleDOI
Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy
Hiroto Izumi,Takayuki Torigoe,Hiroshi Ishiguchi,Hidetaka Uramoto,Yoichiro Yoshida,Mizuho Tanabe,Tomoko Ise,Tadashi Murakami,Takeshi Yoshida,Minoru Nomoto,Kimitoshi Kohno +10 more
TL;DR: Understanding pH regulation in tumour cells may provide new ways of inducing tumour-specific apoptosis, thus aiding cancer chemotherapy.
Journal ArticleDOI
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling.
Sidong Huang,Michael Hölzel,Theo A. Knijnenburg,Andreas Schlicker,Paul Roepman,Ultan McDermott,Mathew J. Garnett,Wipawadee Grernrum,Chong Sun,Anirudh Prahallad,Floris H. Groenendijk,Lorenza Mittempergher,Wouter Nijkamp,Jacques Neefjes,Ramon Salazar,Peter ten Dijke,Hidetaka Uramoto,Fumihiro Tanaka,Roderick L. Beijersbergen,Lodewyk F. A. Wessels,René Bernards +20 more
TL;DR: Inhibition of TGF-βR signaling restores drug responsiveness in MED12(KD) cells, suggesting a strategy to treat drug-resistant tumors that have lost MED12, a component of the transcriptional MEDIATOR complex that is mutated in cancers.
Journal ArticleDOI
Recurrence after surgery in patients with NSCLC
Hidetaka Uramoto,Fumihiro Tanaka +1 more
TL;DR: The superiority of surgery, the reasons for recurrence, the timing and pattern of recurrences, the identification of factors related to Recurrence, current provisions for treatment and perspectives about surgery for patients with NSCLC are discussed.
Journal ArticleDOI
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Seiji Yano,Tadaaki Yamada,Shinji Takeuchi,Keisei Tachibana,Yuko Minami,Yasushi Yatabe,Tetsuya Mitsudomi,Hidenori Tanaka,Tatsuo Kimura,Shinzoh Kudoh,Hiroshi Nokihara,Yuichiro Ohe,Jun Yokota,Hidetaka Uramoto,Kosei Yasumoto,Katsuyuki Kiura,Masahiko Higashiyama,Makoto Oda,Haruhiro Saito,Junji Yoshida,Kazuya Kondoh,Masayuki Noguchi +21 more
TL;DR: High-level HGF expression was detected more frequently than EGFR T790M secondary mutation or MET amplification in tumors with intrinsic and acquired EGFR-TKI resistance in EGFR mutant lung cancer in Japanese patients.
Journal ArticleDOI
Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells.
Hiroto Izumi,Mayu Takahashi,Hidetaka Uramoto,Yoshifumi Nakayama,Tsunehiro Oyama,Ke-Yong Wang,Yasuyuki Sasaguri,Shigeru Nishizawa,Kimitoshi Kohno +8 more
TL;DR: It is found that the expression of the monocarboxylate transporters MCT1 and MCT4, but not MCT5, in human lung cancer cell lines was significantly correlated with invasiveness, and these proteins may be promising targets for the prevention of cancer invasion and metastasis.